- Home
- / CymaBay Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
CymaBay Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$31.1 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.1M | ||||||||||
| General and administrative expense | 4.9M | 8.2M | 8.9M | 9.6M | 12.4M | 14.4M | 19.2M | 17.4M | 23.0M | 25.1M | 52.0M |
| Operating expense total | 9.4M | 24.0M | 25.9M | 25.6M | 31.3M | 72.5M | 103.1M | 53.3M | 93.1M | 132.8M | |
| EBIT | (9.4M) | (24.0M) | (25.9M) | (25.6M) | (21.3M) | (72.5M) | (108.1M) | (52.6M) | (87.6M) | (93.1M) | (101.7M) |
| EBIT margin, % | -327.2% | ||||||||||
| Interest income | 10.0K | 74.0K | 160.0K | 176.0K | 621.0K | 4.0M | 5.3M | 1.6M | 167.0K | 2.0M | 13.5M |
| Interest expense | 43.0K | 18.9M | |||||||||
| Net Income | (10.1M) | (31.9M) | (15.5M) | (26.7M) | (27.6M) | (72.5M) | (102.8M) | (51.0M) | (90.0M) | (106.0M) | (105.4M) |
| EPS | (1.2) | (1.0) |